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Reactive oxygen species, ROSMitochondria play central roles in cell life as a source of energy and in cell death by inducing apoptosis. Many
important functions of mitochondria change in cancer, and these organelles can be a target of chemotherapy. The
widely used anticancer drug doxorubicin (DOX) causes cell death, inhibition of cell cycle/proliferation and
mitochondrial impairment.However, themechanismof such impairment is not completely understood. In our study
weusedconfocal and two-photonﬂuorescence imaging togetherwithenzymatic and respirometric analysis to study
short- and long-termeffects of doxorubicin onmitochondria in various human carcinoma cells.We show that short-
term (b30 min) effects include i) rapid changes in mitochondrial redox potentials towards a more oxidized state
(ﬂavoproteins andNADH), ii)mitochondrial depolarization, iii) elevatedmatrix calcium levels, and iv)mitochondrial
ROS production, demonstrating a complex pattern of mitochondrial alterations. Signiﬁcant inhibition of
mitochondrial endogenous and uncoupled respiration, ATP depletion and changes in the activities of marker
enzymeswere observed after 48 h of DOX treatment (long-term effects) associatedwith cell cycle arrest and death.indiacetate;DOX,doxorubicin;
razone; ROS, reactive oxygen
ncoupling control ratio
x: +43 512 504 27805.
etsov).
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Mitochondria play a central role in energy supply for normal cell
function and also perform many important cellular tasks, such as
induction of apoptosis and programmed cell death, cellular calcium and
redoxhomeostasis [1,2]. On the other hand, important cellular functions
of mitochondria are signiﬁcantly changed in tumor cells and during
chemotherapy [3–5]. Many recent reports show energy metabolism
impairment andmitochondrial alterations toplay a critical role in tumor
progression and resistance to anticancer therapy [4,6]. However,
conﬂicting data were frequently observed and also demonstrate a
clear drug and cell type speciﬁcity. Doxorubicin (DOX) is known as a
powerful anthracycline antibiotic widely used to treat many human
cancers [7,8], but signiﬁcant cardiotoxicity limits its clinical application
[9–14]. Mitochondria are considered to be one of the primary targets of
DOX through mitochondria-mediated apoptosis, remarkable modiﬁca-
tion of mitochondrial membranes (e.g. via binding with cardiolipin),
which is also associated with changes in various mitochondrial
functional parameters and activities of respiratory chain complexes
like complex IV, complex III, phosphate carrier, etc. [15–21]. In addition,an involvement of DOX-induced oxidative stress has been evidenced by
ROS overproduction, alterations in cellular redox state [9,12,17,22,23],
diminished ROS-scavenging activities (e.g. catalase and glutathione
peroxidase) and also by protective effects of various antioxidants such
as Mito-Q [24], melatonin [25] and others. Moreover, doxorubicin
signiﬁcantly damages energy-transferring and -signalling systems like
creatine kinase and AMP-activated protein kinase [26,27]. Also, it is
known that DOX treatment may cause adaptive responses through the
mitochondria and various cellular antioxidant defence systems, poten-
tially contributing to the occurrence of multidrug resistance [28–30].
However, thedetailedmechanisms bywhichdoxorubicin interferewith
mitochondrial function and cellular bioenergetics and, in particular, the
exact sequence and metabolic impact of distinct events during DOX
treatment remain largely unknown.
This study, using confocal ﬂuorescencemicroscopy of mitochondrial
ﬂavoproteins and NADH, high-resolution respirometry of intact cells
and analysis of key mitochondrial and non-mitochondrial enzymes,
separately investigated various short- and long-terms effects of
doxorubicin on mitochondrial functional and enzymatic parameters in
various human carcinoma cells, including colorectal adenocarcinoma
HT-29, DLD-1 and HRT-18 cells, breast tumor MCF-7 and Hs578-T cells.
Taken together, our data demonstrate that DOX treatment results in
several patterns of mitochondrial change: 1) rapid, early effects
were a remarkable shift towards a more oxidized state of mitochondria,
2) decrease in the inner mitochondrial membrane potential and
3) elevated mitochondrial calcium level. These changes preceded
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enzymatic activities (long-term effects). In addition, we show that
mitochondrially located ROS can also be detected rapidly after DOX
addition, most probably due to respiratory chain-produced superoxide
radicals. On the other hand, ROS overproduction and oxidative stress can
also be related to a different mechanism.
2. Materials and methods
2.1. Cell culture
Human colon cancer HRT-18 and HT-29 cell lines and breast cancer
MCF-7 and Hs578-T cell lines obtained from American Type Culture
Collection were used in this study (in some experiments colon
carcinoma DLD-1 cells were also used). Cells were routinely cultured
in RPMI-1640 growth medium supplemented with antibiotics, gluta-
mine and 10% FCS. New cultureswere re-established from frozen stocks
every 3months. Once amonth routine tests were conducted to conﬁrm
that cellswere free ofmycoplasm (mycoplasmdetection kit, Stratagene,
Amsterdam, The Netherlands). For experiments, cells were detached
with trypsin, washed once in medium, and seeded in falcon ﬂasks (12
ml). For respiration and enzymatic analysis, cells were cultured for 48
h in growth medium in the absence or presence of various concentra-
tions of doxorubicin. Cells were then detached with trypsin, washed,
resuspended in the growth medium (1–2 × 106 cells/ml) and used for
further analysis. In confocal imaging experiments, cells were incubated
with doxorubicin using LAB-TEK® chambered microscopic cover-glasses
(“Nalge-Nunc International”, Naperville, USA). ParentalMCF-7 cell lines
were grown in MEM medium, supplemented with 10% FCS, 50 μg/ml
penicillin–streptomycin, 2 mM L-glutamine, and 1 mM sodium
pyruvate (PAA, Linz, Austria) and maintained at 37 °C in a humidiﬁed
atmosphere containing 5% CO2.
2.2. Cell size, count and viability
Casy®-1 Cell Counter and Analyser System model TT (Schärfe
System, Reutlingen, Germany) was used to measure cell size proﬁles
(cell count versus cell size),maximal andmean values of cell diameters,
volumes and cell viability. For this purpose, 100 μl of cell suspensionwas
added to 10 ml of measuring buffer. In addition, a routine trypan blue
test was always used to count viable and non-viable cells.
2.3. FACS analysis
Flow cytometric analysis of cells stained with propidium iodide
(50 μg/ml) was performed using the Becton Dickinson Cytometry
System and CellQuest software. For each analysis, 20,000–30,000
gated events were collected. Cell cycle analysis was performed using
Modﬁt LT (Verity Software House).
2.4. Enzymatic analysis
Three essential enzymes were chosen for the analysis. The activity
of two marker mitochondrial enzymes was assayed: mitochondrial
matrix enzyme citrate synthase (CS) and respiratory chain enzyme
NADH:ubiquinone oxidoreductase (Complex I) located in the inner
mitochondrial membrane. In addition, the activity of cytosolic enzyme
lactate dehydrogenase (LDH) was also measured. Activities of all
enzymeswere determined in cells frozen in liquid nitrogen and stored
at −80° C using spectrophotometry at 30° C in medium supplemen-
ted with 0.1% Triton X-100 [31,32].
2.5. Measurement of cellular ATP content
CellularATP contentwasmeasuredusing the luceroferin-luceroferase
system (bioluminescent cell assay kit, “Sigma”) and multiplateluminometer. ATP was extracted from cells after protein precipitation
using 0.5 M perchloric acid and subsequent neutralization with 1 M
K2CO3 and 100 mM HEPES-K (pH 7.4), following centrifugation at
10,000g for 5min to remove precipitates. The ATP calibration curve was
used for ﬁnal analysis.
2.6. Cellular respiration
Oxygen consumption of the cells was measured with a titration-
injection respirometer (OROBOROS® Oxygraph, Innsbruck, Austria) in
RPMI growth medium [33], before and after addition of the
mitochondrial uncoupler FCCP (2–4 μM) at 30 °C, assuming an O2
solubility of 10.5 μmol l−1 kPa−1 (1.4 μmol l−1 mmHg−1). DatLab
software (Oroboros, Innsbruck, Austria) was used for data acquisition
and analysis. Respiration rates were expressed in pmol of O2 per
second, per 106 cells. Both endogenous and uncoupled respiration
rates were linearly dependent on the cell density in range 0.1–6 × 106
cells/ml. Also, mitochondria-speciﬁc inhibitors blocked respiration
conﬁrming that oxygen consumptionwas due to the respiratory chain
(data not shown).
2.7. Measurement of ROS production
ROS productionwasmeasured by loading cells with 20 μMDCF-DA
(2,7-dichlorodihydroﬂuorescein diacetate) or with 5 μM MitoSOX™
Red for 30 min at room temperature in the dark. After washing with
PBS, cells were further processed for analysis using spectroﬂuorimetry
or confocal microscopy [34]. ROS production was measured using a
Shimadzu RF-5301PC spectroﬂourophotometer at room temperature
and results were expressed as arbitrary units (a.u.) per min, per 106
cells. Fluorescence intensity was linearly proportional to cell concen-
tration up to 5 × 106 cells per ml (data not shown).
2.8. Confocal imaging of mitochondrial redox state (autoﬂuorescence of
mitochondrial ﬂavoproteins and NADH)
Mitochondrial ﬂavoprotein and NADH autoﬂuorescence were
imaged simultaneously [35–38] using a confocal microscope (LSM510
NLO, Zeiss)with a 40× (NA 1.2)water immersion lens. The use of such a
water immersion objective prevented geometric aberrations. The
autoﬂuorescence of ﬂavoproteins was excited with the 488-nm line of
anargon laser, and the laser outputpowerwas set toanaverageof8mW
(about 60%). Fluorescence was collected through a 510-nm dichroic
beam splitter and a 505- to 550-nm band-pass ﬁlter. The pinhole
aperture was set to one Airy disk unit. NADH autoﬂuorescence was
imaged by means of two-photon excitation using a femtosecond
pulsed infra-red laser (Tsunami+MilleniaVIII, SpectraPhysics). Pulse
frequencywas set at 100MHzwith a pulsewidth of 100 fs. The infra-red
linewas tuned to 720nm. Laser output powerwas set to 400mW(70%).
The ﬂuorescence signals were collected through a multi-line beam
splitter with maximum reﬂections at 488±10 nm (for rejection of
the 488-nm line) and above 700 nm (for rejection of infra-red
excitation). A second 490-nm beam splitter was used to discriminate
the NADH signal from the ﬂavoprotein signal. Then the ﬂavoprotein
signal was passed through a 500- to 550-nm band-pass ﬁlter with an
additional infra-red rejection ﬁlter before being collected through
a pinhole (oneAiry disk unit). TheNADH signalwas redirected to a 390-
to 465-nm band-pass ﬁlter with an additional infra-red rejection ﬁlter.
2.9. Imaging analysis of mitochondrial membrane potential and
mitochondrial calcium
In order to analyze mitochondrial distribution and mitochondrial
inner membrane potential, cells were incubated for 30 min at room
temperature with 50 nM tetramethylrhodamine ethyl ester (TMRE).
TMRE ﬂuorescencewas excitedwith a 543-nmhelium-neon laser; the
Fig. 1. Effect of various doxorubicin concentrations on cell detachment (A) and viability
(B). MCF-7 (A) or DLD-1 (B) cells were incubated 48 h with different DOX concentrations
in RPMI-1640medium. (B) Cell viability was estimated by trypan blue assay, degree of cell
death was determined by ﬂow cytometry using propidium iodide (PI) staining.
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ﬂuorescence signals were collected through a multi-line beam splitter
with maximum reﬂections at 488±10 nm (for rejection of the 488-
nm line) and at 543 nm (for rejection of the 543-nm line). A second
545-nm beam splitter was used to discriminate the TMRE signal from
the ﬂavoprotein signal. Then the ﬂavoprotein signal was passed
through a 505-nm long-pass ﬁlter before being collected through a
pinhole (one Airy disk unit). The TMRE signal was redirected to a 560-
nm long-pass ﬁlter before being collected through a pinhole (one Airy
disk unit). To analyze the level of mitochondrial matrix calcium, cells
were preloaded with ﬂuorescent Ca2+-speciﬁc probe Rhod-2. For this,
cells were incubated for 30min at room temperaturewith 5 μMRhod-
2. Rhod-2 has a net positive charge allowing its speciﬁc accumulation
in mitochondria. Confocal imaging of Rhod-2 ﬂuorescence was
performed as described for TMRE. Rhod-2 as TMRE ﬂuorescence was
also imaged simultaneously with ﬂavoprotein and NADH ﬂuores-
cence. Time series were acquired during 0–30 min with 30 s intervals.
The notion that TMRE and Rhod-2 are speciﬁc mitochondrial
indicators was evidenced by their full colocalization with mitochon-
drial ﬂavoproteins as integral components of the mitochondrial inner
membrane and mitochondria-speciﬁc probe MitoTracker Green (data
not shown).
2.10. Imaging of ROS production
ROS production was visualized in cells loaded with 20 μM of 2′,7′-
dichlorodihydroﬂuorescein diacetate, (DCF-DA, Sigma) for 20 min at
room temperature. ROS-induced green ﬂuorescence of DCF was
imaged using 488-nm laser excitation. The laser power was set to
1–3%. Importantly, this power setting allowed complete discrimina-
tion of DCF ﬂuorescence and the autoﬂuorescence originating from
the oxidized form of mitochondrial ﬂavoproteins. The 515- to 530-nm
emission range was used to monitor an increase in dichloroﬂuores-
cein, the oxidized product of DCF-DA.
2.11. Quantitative assessments of the ﬂuorescence signal
In all imaging studies the intensity of ﬂuorescence (grey value)
was analyzed in the areas of interest (mitochondria-rich areas) using
“Scion Image” software for Windows (Release Beta 4.0.2. NIH, USA).
Background ﬂuorescence (no cells area) was subtracted from the
corresponding signal. In each measurement (n=3–6), ﬂuorescent
signals from 4 to 6mitochondria-rich areas (in regions of interest, Roi)
of 10–20 cells were averaged.
2.12. Reagents
Rhod-2 was obtained from “Molecular Probes Inc.” (Leiden, The
Netherlands); other reagents (TMRE, DCF-DA, etc.) were purchased
from “Sigma” (Vienna, Austria).
2.12.1. Data analysis
All data are presented as means±SD. Statistical analyses were
performed using Student's t-test and Pb0.05 was taken as the level of
signiﬁcance.
3. Results
3.1. Effects on cell size, cell cycle and viability
Mitochondrial confocal imaging, enzymatic and high-resolution
respirometry approaches were used to study multiple effects of
doxorubicin (short- and long-term) on various important parameters
of mitochondria and to correlate these with cell viability. Short
treatment of cells with doxorubicin (less than 1 h of incubation,
DOX concentration range: 1–10 μg/ml) had no effect on cell viability(data not shown). Alternatively, prolonged incubation with the drug
resulted in time- and concentration-dependent cell death and
detachment (up to 90% cells after N48 h of incubation following
incubation with 10μg/ml DOX) in all cell types used in the study
(Fig. 1A). This cell detachment was always in parallel with a decrease
in cell viability analyzed by trypan blue staining (Fig. 1B) and with
increased percentage of dead cells using ﬂow cytometry (FACS) and
propidium iodide (PI) staining. It was recently reported that DOX
inhibits cell proliferation via cell cycle arrest in the G(2)/M phase in
murine lymphocytes [39]. Similar to this study, when using FACS
analysis we showed that doxorubicin treatment induced a concen-
tration-dependent accumulation of the human carcinoma cells in the
G(2)/M phase, demonstrating inhibition of cell proliferation by cycle
arrest in this phase (Fig. 2). Using the Casy® Cell Counter and Analyser
System, cell size proﬁles (cell count versus cell size) were analyzed
and showed a signiﬁcant shift in cell size distribution after incubation
with DOX (cell diameter 15±0.7μm and 17±0.5μm, for control and
DOX-treated but still attached MCF-7 cells, respectively, Pb0.01). The
measurements were performed after 48 h of incubation with the
drug (10 μg/ml), showing similar changes for other cells used in the
study (also in colon carcinoma cells). Modiﬁcations in cell morphol-
ogy and size induced by DOX have been shown also in cultured
leukemia cells [40].
Fig. 2. FACS analysis of the effect of various doxorubicin concentrations on cell cycle in
human breast carcinoma Hs578-T cells. Incubation with doxorubicin (48 h) resulted in
a signiﬁcant dose-dependent increase in cells arrested in the G2/M phase of the cell
cycle. (A) Control. (B) 1.0 μg/ml doxorubicin. (C) 5.0 μg/ml doxorubicin. (D) 10 μg/ml
doxorubicin.
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in the inner membrane potential and mitochondrial matrix calcium
The mitochondrial confocal imaging approach was used for rapid
analysis of fast changes in several important mitochondrial para-
meters in living, conﬂuent cells after addition of DOX (Fig. 3A–D).
Simultaneous confocal imaging of mitochondrial ﬂavoproteins and
NADH autoﬂuorescence (using two-photon excitation) as redox state
indicators, Rhod-2 ﬂuorescence as indicator of mitochondrial matrix
calcium, and TMRE ﬂuorescence as sensor of the mitochondrial
inner membrane potential in human carcinoma cells demonstrated
remarkable and rapid (b30 min) changes in these parameters after
addition of 10 μg/ml DOX (Fig. 3C). Quantiﬁcation of the results of
these experiments, including statistics, is summarized in Table 1. It
can be seen that in all cell types used in the study, doxorubicin
treatment resulted in a signiﬁcant (almost 2-fold) increase in
autoﬂuorescence intensity of mitochondrial ﬂavoproteins (green,
ﬂuorescent in oxidized state), together with a clear decline in the
NADH autoﬂuorescence signal (blue, only ﬂuorescent in its reduced
state), both indicating oxidation of these two important markers of
the mitochondrial redox state and thus showing rapid transition of
mitochondria to their signiﬁcantlymore oxidized state (Fig. 3C, Table 1).
Moreover, simultaneousmonitoring of TMRE ﬂuorescence demonstrat-
ed that doxorubicin treatment also resulted in a quick drop in
membrane potential (Fig. 3D), visible as a strong decline in ﬂuorescence
intensity, as a result of less mitochondrial membrane potential and
decreased sequestration of this potentiometric-sensitive dye. In parallelsets of experiments, an increase in the mitochondrial matrix calcium
was observed from the remarkable increase in ﬂuorescence intensity
of the mitochondrial calcium-sensitive probe Rhod-2 (Fig. 3C) parallel
to the changes described above. Importantly, all cell types (MCF-7, HTR-
18, HT-29 and Hs578-T) exhibited a similar extent and patterns of
changes (Table 1).
3.3. Mitochondrial respiratory function and coupling in DOX-treated
cells
Effects of DOX treatment on mitochondria were also estimated by
measuringmitochondrial respiratory function as a sensitive indicator of
cell injury and adaptation. Importantly, no changes in mitochondrial
respirationwere found after brief incubation (b1 h)withDOX following
addition of the drug to the oxygraph chamber during respiration
measurement (or titration with DOX in the range of 1–10 μg/ml, data
not shown). In contrast, long-term cell exposure to DOX (48 h)
signiﬁcantly decreased rates of mitochondrial respiration (Fig. 4A).
Moreover, FCCP-stimulateduncoupled respirationwas also signiﬁcantly
decreased, reﬂecting diminished respiratory capacity of mitochondria
in intact cells. Notably, most pronounced decline was observed in
breast carcinoma MCF-7 cells (Fig. 4A). From these experiments, in
addition to information on absolute respiratory ﬂuxes (endogenous and
uncoupled), the uncoupling control ratio (UCR), a parameter showing
the degree of respiratory stimulation by FCCP, was also derived. This
ratiowas also signiﬁcantly reduced afterDOX treatment (Fig. 4B). Again,
more pronounced decline in UCR was observed in MCF-7 cells (from
3.60±0.09 to 1.90±0.11).
3.4. Effects of DOX on cellular ATP level
Consistent with the results of mitochondrial respiration analysis
showing functionally disturbed mitochondria after long-term (48 h)
DOX treatment, incubation with DOX also resulted in a signiﬁcant
decline in cellular ATP content measured after the same treatment
time (Fig. 4C). Certainly, this decline can be a consequence of both the
lower rates of mitochondrial respiration and the lower efﬁcacy
(coupling) of oxidative phosphorylation observed in the study.
3.5. Enzymatic analysis of DOX-treated cells
In addition to imaging analysis and high-resolution respirometry,
changes in the activities of key marker mitochondrial and non-
mitochondrial enzymes were tested in carcinoma cells after long-term
incubation (48 h)withDOX. This analysis included an assessment of the
activities of mitochondrial matrix enzyme citrate synthase (CS),
mitochondrial respiratory complex I and cytosolic enzyme LDH
(Table 2). It can be seen that DOX treatment remarkably diminished
the activity of respiratory complex I inMCF-7 cells,while the activities of
other tested enzymes in DOX-treated but still attached carcinoma cells
were not signiﬁcantly changed (Table 2).
3.6. Detection of DOX-induced ROS production
Signiﬁcantly more oxidized states of mitochondrial ﬂavoproteins
and NADH observed after short-term treatment with DOX (20–30 min,
see above) are well consistent with mitochondrial ROS generation
detected by the ﬂuorescent indicator DCF-DA using both confocal
microscopy and spectroﬂuorometry (Fig. 5; for isolated cardiomyocytes
see also ref. [41]). Confocal imaging analysis of DCF-DA ﬂuorescence in
cells double-loaded with DCF-DA and mitochondrial membrane
potential-sensitive probe TMRE demonstrated that DOX-induced ROS
production in human carcinoma cells is mostly colocalized with
mitochondria (Fig. 5A), indicating a mitochondrial origin of the DOX-
induced ROS. Moreover, using spectroﬂuorometry analysis and the
same ROS indicator we show that the mitochondrial uncoupler FCCP
Fig. 3. Representative confocal imaging of mitochondrial functional changes in MCF-7 cells after DOX treatment. (A) Simultaneous imaging of autoﬂuorescence of mitochondrial
ﬂavoproteins (ﬂavo, green) andNADH(blue) asmitochondrial redox state indicators andﬂuorescence of TMRE as innermembrane potential-sensitive probe. (B) Simultaneous imaging of
mitochondrial ﬂavoproteins (ﬂavo) and NADH and mitochondrial matrix calcium (cells were stained with Rhod-2). Scale bar=10 μm. (C) Upper panel, representative changes in
ﬂuorescence ofﬂavoproteins (ﬂavo),NADHandTMREafter20minof incubationwithDOX. Lowerpanel, representative changes inﬂuorescence ofmitochondrial calcium indicatorRhod-2
after 20 min of incubation with DOX. Bar, 20 μm. (D) Representative time-course (kinetics) of DOX effect on mitochondrial inner membrane potential (ΔΨ) analyzed by monitoring of
TMRE ﬂuorescence (a.u., arbitrary units).
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membrane potential, whereas the inhibitor of mitochondrial complex
III, antimycin A, stimulated ROS production (Fig. 5B), thus also pointing
to the mitochondrial origin of ROS. Similar results were obtained using
another ROS-sensitive probe MitoSOX™ Red (data not shown).
However, some generation of non-mitochondrial ROS can not be
completely excluded, for example bymembrane-boundNADPHoxidase
(NOX) [42], or due to direct involvement of ROS-producing DOX
chemistry [17,22].
4. Discussion
Doxorubicin (DOX) is a widely used chemotherapeutic drug for
the treatment of acute leukemia, lymphomas and different types of
solid tumor, but it can produce complications leading also to
multidrug resistance. Although the mitochondrial dysfunction and thesevere inhibition/inactivation of certain mitochondrial systems have
been implicated as important pathways of the DOX action associated
with its remarkable cardiotoxicity (cardiomyopathy), the exact molec-
ular mechanisms are still unclear. Using colon HT-29 and HRT-18 and
mamma MCF-7 and Hs578-T cancer cell lines we conﬁrmed previous
ﬁndings observed in murine lymphocytes [39], namely that DOX
inhibits cell proliferation through cell cycle arrest at the G(2)/M phase
(Fig. 2) in a time- and dose-dependent manner, also causing massive
cell death (Fig. 1B).
Simultaneous imaging of autoﬂuorescence of mitochondrial ﬂavo-
proteins and NADH (two-photon excitation) as sensitive indicators
of mitochondrial redox potentials [43,44] was performed at the single
cell and single organelle level in response to short-term (20–30 min)
DOX treatment. Importantly, the redox state of ﬂavoproteins located in
the inner mitochondrial membrane is in balanced equilibriumwith the
redox state of mitochondrial NAD(P)H [38]. Accordingly, a rapid strong
Table 2
Changes in the enzyme activities of mitochondrial matrix enzyme citrate synthase (CS),
mitochondrial respiratory chain complex I and cytoplasmic enzyme lactate dehydro-
genase (LDH) in DOX-treated human carcinoma cells (long-term effects).
Cell type Complex I CS LDH
MCF-7 control 29±9 67±20 130±30
+DOX 13±3** 61±17 166±40
Hs578-T control 20±5 66±16 92±8
+DOX 18±7 60±17 60±17
HT-29 control n.d. 69±15 54±19
+DOX 71±20 55±19
DLD-1 control n.d. 55±11 35±11
+DOX 63±20 37±9
Enzyme activities are given in mU per 106 cells. Cells were incubated with doxorubicin
(10μg/ml) for 48h at 37 °C in the culturemedium. Enzyme activitiesweremeasured at 37 °C
as described in the “Materials and methods” section. ± shows SD; n= 3–6; **signiﬁcantly
different from corresponding control, P b 0.01. n.d., not determined.
Table 1
Quantitative analysis of alterations in ﬂuorescence intensity of mitochondrial ﬂavopro-
teins, NADH, TMRE and Rhod-2 in various human carcinoma cells after short-term
incubation with doxorubicin.
Cell type Flavoproteins NADH TMRE Rhod-2
MCF-7 165.5±28.0** 83.4±3.9** 26.8±1.5*** 161.2±38.6**
Hs578-T 148.0±12.5** 80.5±2.9** 67.6±1.7*** n.d.
HRT-18 135.5±9.3** 90.5±18.9 60.8±6.3*** 135.2±9.8*
HT-29 150.5±14.9** 88.2±7.7 49.8±2.3*** n.d.
Fluorescence intensity wasmeasured before and after cells incubationwith DOX (10 μg/ml,
20 min) in chambered microscopic cover-glasses, as grey value in the mitochondria-rich
areas (regions of interest, Roi) within cells, using inverted confocal ﬂuorescent images and
the “Scion Image for Windows” program. Values are given as percentage of the
corresponding controls (before DOX addition) and after background ﬂuorescence
correction. Data for 4–6 cell areas in 10–20 different cells are averaged. ± shows SD; n =
4–6; signiﬁcantly different from corresponding controls, *Pb0.05, **Pb0.01, ***Pb0.001. n.d.,
not determined.
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after DOX addition was seen parallel with a remarkable decrease in
mitochondrial NADH ﬂuorescence (Fig. 3A, Table 1), both reﬂecting a
general shift of mitochondria towards their more oxidative state.
Notably, due to cross-talk betweenmitochondrial and cytoplasmic NAD
(P)H this shiftmay lead to signiﬁcant alterations (perturbations), also in
the overall cellular redox state. Moreover, cellular dehydrogenases and
various metabolic pathways continuously produce NAD(P)H, which
may operate directly as an intracellular antioxidant as long as it is
regenerated [45]. However, our confocal microscopy imaging study
showed that both NAD(P)H and ﬂavoprotein ﬂuorescence exhibited a
predominant localization in mitochondria (Fig. 3A and B). We demon-
strated that the intensity of both ﬂuorescence signals was sensitiveFig. 4. Decrease inmitochondrial respiratory function andATP content invarious carcinoma
cells after treatment with doxorubicin. (A) Respiration rates were measured at 37° C in
control and DOX-treated cells after 48 h of incubation, before (endogenous respiration) and
after addition of FCCP (uncoupled respiration). (B) The respiratory uncoupling ratio (UCR)
was calculated as the ratio of uncoupled and endogenous respiration. (C) Cellular content of
ATP in control and DOX-treated cells. Incubation conditions with DOX are described in
“Materials and methods”. Error bars show±SD; n=3–6; signiﬁcantly different from
corresponding controls: *Pb0.05, **Pb0.01, ***Pb0.001.to DOX treatment and also to changes in the mitochondrial metabolic
state, like the presence or absence of mitochondrial substrates
[35,37,38,46,47], inhibitors, different concentrations of oxygen, as well
as to changes in different models of cell injury [48]. Both the cellular
redox state and the overall cellular NAD(P)H pull depend on the
complex interrelations of many cellular systems [45]. The regenerative
function ofmany antioxidative and ROS-scavenging enzymes in the cell
requires NADH or NADPH, both of which are produced by various
dehydrogenases and by the mitochondrial Krebs cycle. Moreover, the
transient oxidation of NAD(P)H and thus changes in the cell redox
state can be closely associated with a decrease in total cellular
antioxidant capacity as well as with an increase in mitochondrial or
non-mitochondrial ROS production.
Since the confocal imaging technique allows concomitant detec-
tion of ﬂuorescence probes with different spectral characteristics,
analysis of the redox state of mitochondria can be combined with
imaging of mitochondrial membrane potential monitored by TMRE
ﬂuorescence (Fig. 3A), or mitochondrial matrix calcium analyzed by
Rhod-2 ﬂuorescence (Fig. 3B), both also colocalized with MitoTracker
Green, speciﬁc for mitochondria (see “Materials andmethods”). Using
such a combined imaging approach we showed that the mitochon-
drial shift towards their more oxidized state took place parallel with
signiﬁcant mitochondrial depolarization (Fig. 3C and D), which occurs
(as shown in separate experiments) simultaneously with an increase
in mitochondrial calcium levels. Also, a rapid decrease in mitochon-
drial transmembrane potential (ΔΨm) was obtained using another
potential-sensitive dye JC-1 [49]. In these experiments, authors show
that, with the progression of exposure time, the early depolarization
of the mitochondrial membrane was followed by a transient reversion
to normal ΔΨm (see ref. [49]). Notably, calcium and ROS changes can
also be transient in various carcinoma cells under laser-induced
photo-oxidative stress (our unpublished data). It is well known that
an accumulation of Ca2+ in mitochondria and a drop in mitochondrial
membrane potential can be associated with ROS production and that
both are prerequisite steps for the induction of mitochondrial
permeability transition (MPT) and subsequent cell death by apoptosis
or necrosis [50,51]. Also, the rapid rise in mitochondrial Ca2+ after
doxorubicin addition observed in our study is well consistent with
previous ﬁndings showing a greater than 2-fold increase in cytosolic
Ca2+ in DOX-treated cultured cardiomyocytes [52,53]. These data
suggest that doxorubicin-induced alterations in mitochondrial Ca2+
homoeostasis (see also [54]) are associated with a failed energy (ATP)
production and thus a decrease in ATP level, further resulting in cell
injury and cardiotoxicity.
To further deﬁne the effects of doxorubicin onmitochondria and cell
energy metabolism, we measured cellular respiration (Fig. 4A and B)
and ATP content (Fig. 4C). Cellular respiration rate reﬂects normal
Fig. 5. DOX-induced mitochondrial ROS production. (A) Representative confocal imaging of DOX-induced mitochondrial ROS production in MCF-7 cells after 20 min of incubation
with DOX. Cells were double-stained with 20 μM DCF-DA and 100 nM TMRE. Bar, 10 μm. (B) Effects of mitochondrial uncoupler FCCP and speciﬁc inhibitor of mitochondrial
respiratory complex III antimycin A (Ant. A) on DOX-induced mitochondrial ROS production (closed bars). Error bars show±SD; n=4; signiﬁcantly different from corresponding
controls without DOX (open bars); ***Pb0.001, ##Pb0.01.
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on the factors of cellular metabolism like ADP concentration. Alterna-
tively, FCCP-stimulated respiration reﬂects the maximal respiratory
capacity of uncoupled mitochondria, which can also be dependent on
availability and concentrations of various metabolites, substrates and
Ca2+. Importantly, a signiﬁcant decline in respiration rates was ob-
served only after long- but not short-termdrug treatment. This indicates
that initial changes in mitochondrial redox state, membrane potential
and calcium, well visible with confocal imaging, had no effect on
mitochondrial respiratory function. More probably, speciﬁc damage to
or partial inhibition of mitochondrial respiratory chain complexes can
be an expected explanation for the respiratory decline after long-term
incubation. No signiﬁcant changes in CS activity (frequently used
marker of mitochondrial content, see Table 2) also point to a speciﬁc
respiratory chain defect, rather than general loss ofmitochondrial mass.
Previous ﬁndings have shown mitochondrial dysfunction [55] and
inactivation of mitochondrial systems such as complexes I, III, and IV
(COX), and also phosphate carrier [18,20,21,56,57] and ATP-ADP
translocase [58], due to binding of DOX to cardiolipin of the inner
mitochondrial membrane [19,20,59]. This can remarkably contribute to
the inhibition of mitochondrial activity in DOX-treated mitochondria
[27,60]. Alternatively, in contrast to our and some other previous
ﬁndings, in Jurkat and HL-60 cells, doxorubicin treatment increased
cellularmitochondrial oxygen consumption after 24 h of exposure to the
drug [61]. However, the same group showed contradicting results
regarding effects of DOX on mitochondrial respiration, demonstrating
that incubation of cells with high-dose doxorubicin (5–20 μM) caused a
signiﬁcant inhibition of mitochondrial respiration [62].
In addition to the information on absolute respiratory ﬂuxes, an
important ratio can be derived from our protocol. The uncoupling
control ratio (UCR) is the ratio of the uncoupled rate of respiration to
endogenous respiration, and this parameter also signiﬁcantly declined
in DOX-treated cells (Fig. 4B), consistently with previous ﬁndings
obtained in DOX-treated cardiac mitochondria [54]. The UCR valuereﬂects the respiratory reserve capacity, and it may decline due to
increased ADP-stimulated endogenous respiration (e.g. because of
higher energy demand), due to the uncoupling of mitochondria or to
decreased respiratory capacity at constant endogenous respiration.
Interestingly, cell treatment with DOX signiﬁcantly changed the
sensitivity of mitochondria to the mitochondrial uncoupler FCCP.
Titration experiments using a stepwise increasing FCCP and that were
routinely performed to deﬁne its optimal concentration (about 4 μM in
control cells) demonstrated that a signiﬁcantly greater concentration
of FCCP was required in DOX-treated cells (about 20 μM) in order to
obtain a stimulatory effect similar to that obtained in control cells.
The titration curve was remarkably shifted to the right probably due to
DOX-induced conformational changes in the mitochondrial inner
membrane. Noticeably, the sensitivity to the uncoupler (FCCP) can be
signiﬁcantly dependent on the conformational state of the mitochon-
drial innermembrane(e.g. changes in itsﬂuidity, regularity, etc.). On the
other hand, it iswell known thatDOXmay strongly interactwith certain
phospholipids of thismembrane. In particular, DOXhas a high afﬁnity to
cardiolipin [20,59,63], causing thus changes in membrane physico-
chemical properties. The signiﬁcantly decreased ATP level found in
DOX-treated cells (Fig. 4C) points to the major role of mitochondrial
oxidative phosphorylation in maintaining energy status in human
carcinoma cells despite the expected bioenergetic shift towards a more
glycolytic pathway, which is a widely accepted characteristic of all
cancers (Warburg effect), thus assuming a secondary role of mitochon-
dria in ATP synthesis in tumors.
It has been demonstrated that DOX exposure leads to rapid reactive
oxygen species (ROS) production by means of various mechanisms
[9,22,52,55,64,65]. Many studies support the theory that mitochondria
are a primary target of DOX-induced oxidative stress, both acute and
long-term, and our ﬁndings are in good agreement with this concept.
The role of ROS in DOX-induced cell death has been demonstrated
using both in vivo and in vitromodels [23]. Additional indirect evidence
for ROS involvement is that DOX-induced cell death can be attenuated
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DOX cardiotoxicity is related to ROS induction with subsequent
mitochondrial and cell injury [9,25,52]. Also, the mitochondrial origin
of ROS can be partially conﬁrmed by the cardioprotective effects of
the speciﬁc mitochondria-targeting antioxidant Mito-Q during DOX-
induced cardiomyopathy [24]. Our confocal imaging experiments,
using DCF ﬂuorescence as intracellular ROS indicator, demonstrate that
ROS was rapidly produced upon DOX addition parallel with changes in
mitochondrial redox state and membrane potential. Importantly,
imaging analysis conﬁrmed that ROS production in human carcinoma
cellswasmainly colocalizedwithmitochondria double-stainedwith DCF
and speciﬁc mitochondrial probe TMRE (Fig. 5A). Also, clear effects of
speciﬁcmitochondrial agents: uncoupler FCCP and inhibitor antimycin A
on ROS generation further indicated their mitochondrial origin (Fig. 5B).
However, from our data we can not distinguish whether DOX-induced
ROS were direct causes of the more oxidized mitochondrial state and
elevated Ca2+, or whether ROS were produced in response to the redox
shifts and mitochondrial depolarization. Further experiments will be
necessary to determine a consequence of these events.
Mitochondrial cytochrome c release plays a key role in the pathway
of apoptosis activation [66]. It has been shown that DOX induces
remarkable, dose-dependent cytochrome c release and execution of the
caspase-dependent apoptosis [23]. Cytochrome c release from mito-
chondria can be induced by elevated calcium or ROS and can be blocked
by cyclosporin A, pointing to the involvement of permeability transition.
Peroxidation of cardiolipin induces cytochrome c detachment from the
innermitochondrialmembraneandrelease into theextra-mitochondrial
environment. ROS, therefore, may play a key role in mitochondrial
cytochrome c release [23]. Also, redox state of cytochrome c inﬂuences
its detachment from the inner mitochondrial membrane. Moreover,
oxidative damage to respiratory chain may lead to increased ROS
production thatwill inducemore cytochrome c release. In the sameway,
loss of cytochrome c can stimulate mitochondrial ROS formation, thus
providing an ampliﬁcation effect. Previous reports have shown that
cytochrome c depletion can lead to a reduction of both mitochondrial
membrane potential and respiratory function [67]. However, some
studies show that cytochrome c release is not directly dependent on
mitochondrial membrane depolarization [68] and ΔΨm drop alone
seems not enough to induce apoptosis [69]. Also, it is still unclear to
which extent apoptotic cytochrome c release can diminish mitochon-
drial respiration. One limitation of this study is that all confocal
ﬂuorescent measurements (redox state, ΔΨm, calcium) were per-
formed using conﬂuent, attached cells (similar to the normal conditions
of cell growing), whereas respirometry and enzymatic analyses always
require cells in suspension. This difference may partially explain an
apparent discrepancy that brief incubation with DOX signiﬁcantly
decreases mitochondrial membrane potential (up to ~30% of control)
without changes in mitochondrial respiration. Another explanation can
be related to the important problem of a reversibility of the observed
effects after different times of DOX treatment, which certainly deserves
further investigation.
Taken together, our data evidence that DOX-induced cell death is
associated with mitochondrial respiratory chain defects and reduced
levels of cytosolic ATP, but these declines weremanifested signiﬁcantly
later after mitochondrial redox state shifts, ROS production, decrease
in mitochondrial membrane potential and increased mitochondrial
Ca2+ levels. New information about distinct effects of doxorubicin
on mitochondrial function, as well as their metabolic consequences
may provide a rational means of understanding the speciﬁc role of
mitochondria in chemotherapy and the molecular mechanisms of
doxorubicin chemoresistance. Moreover, detecting changes in redox
state and other mitochondrial alterations can be useful for detecting
chemotherapy responses in vivo. In future the results of this study can
be used to develop new methods for evaluating the efﬁcacy of
chemotherapy in cancer patients based on an analysis of mitochondria
using human biopsies.Acknowledgement
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